These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22083188)

  • 21. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.
    Cardenal F; Arnaiz MD; Morán T; Jové J; Nadal E; Porta R; Solé JM; Brao I; Palmero R; Fuentes R; Núñez I; Caveda E; Cassinello A
    Lung Cancer; 2011 Oct; 74(1):69-74. PubMed ID: 21353323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.
    Malhotra B; Evans T; Weiss J; Eaby B; Stonehouse-Lee S; Sherry V; Langer CJ
    Clin Lung Cancer; 2010 May; 11(3):192-7. PubMed ID: 20439196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial.
    Gervais R; Robinet G; Clément-Duchêne C; Denis F; El Kouri C; Martin P; Chouaki N; Bourayou N; Morère JF
    Lung Cancer; 2013 May; 80(2):185-90. PubMed ID: 23434351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
    Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
    Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
    J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)].
    Tredaniel J; Mornex F; Barillot I; Diaz O; Hennequin C; Le Pechoux C; Lavole A; Giraud P; Souquet PJ; Teixeira L; Vaylet F; Zalcman G; Baudrin L; Morin F; Milleron B
    Rev Mal Respir; 2011 Jan; 28(1):51-7. PubMed ID: 21277474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study.
    Kawano Y; Ohyanagi F; Yanagitani N; Kudo K; Horiike A; Tanimoto A; Nishizawa H; Ichikawa A; Sakatani T; Nakatomi K; Hagiwara S; Ninomiya H; Motoi N; Ishikawa Y; Horai T; Nishio M
    Anticancer Res; 2013 Aug; 33(8):3327-33. PubMed ID: 23898099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.
    Honoré PH; Joensen SJ; Olsen M; Hansen SH; Mellemgaard A
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):349-57. PubMed ID: 24934863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
    Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
    J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for Japanese patients with advanced non-squamous non-small-cell lung cancer -- a retrospective analysis].
    Yamaguchi T; Nakanishi T; Hayashi M; Uozu S; Okamura T; Morishita M; Takeyama T; Minezawa T; Morikawa S; Niwa Y; Mieno Y; Kato A; Hoshino T; Isogai S; Okazawa M; Imaizumi K
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):183-7. PubMed ID: 25743136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
    Yu YF; Chen ZW; Zhou Z; Song ZB; Li ZM; Jian H; Zhang YF; Lu S
    Chemotherapy; 2010; 56(6):472-7. PubMed ID: 21099219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
    Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
    Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
    [No Abstract]   [Full Text] [Related]  

  • 36. Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).
    Galetta D; Pisconti S; Cinieri S; Pappagallo GL; Gebbia V; Borsellino N; Maiello E; Rinaldi A; Montrone M; Rizzo P; Marzano N; Sasso N; Febbraro A; Colucci G
    Clin Lung Cancer; 2011 Nov; 12(6):402-6. PubMed ID: 21831718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).
    Hattori Y; Satouchi M; Katakami N; Fujita S; Kaji R; Hata A; Urata Y; Shimada T; Uchida J; Tomii K; Morita S; Negoro S
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):17-23. PubMed ID: 24141372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies.
    Surmont V; Smit EF; de Jonge M; Aerts JG; Nackaerts K; Vernhout R; Gras J; Van Wijk A; Phernambucq EC; van Meerbeeck JP; Senan S; Kraaij CJ; Chouaki N; Praag J; van Klaveren RJ
    Lung Cancer; 2010 Sep; 69(3):302-6. PubMed ID: 20096951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.
    Wislez M; Barlesi F; Besse B; Mazières J; Merle P; Cadranel J; Audigier-Valette C; Moro-Sibilot D; Gautier-Felizot L; Goupil F; Renault A; Quoix E; Souquet PJ; Madroszyck A; Corre R; Pérol D; Morin F; Zalcman G; Soria JC
    J Clin Oncol; 2014 Apr; 32(12):1256-61. PubMed ID: 24638013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.